Objective

To provide emerging good practice guidance for addressing preference heterogeneity in choice data, specifically from discrete choice experiments (DCEs) or best-worst scaling (BWS) studies.

Rationale

Health preference research (HPR) typically quantifies trade-offs that patients, caregivers, or physicians are willing to make between clinical and non-clinical benefits, risks, administration and other healthcare aspects. While many HPR studies are concerned with average preferences, ‘one size fits all’ decisions and policies ignoring heterogeneity in preferences and treatment priorities can result in unintended consequences. Given the lack of consensus-based recommendations and an increasing number of complex models addressing heterogeneity, addressing this gap in guidance is important to improve overall healthcare decision making.

Co-Chairs:

Sebastian Heidenreich, MSc, PhD, BSc

Senior Director, Patient Preferences, Evidera
London, LON, United Kingdom

Axel Mühlbacher, PhD

Professor, HS Neubrandenburg
Neubrandenburg, MV, Germany

Leadership Group

Marco Boeri, MSc, PhD, BSc

Director of Preference Research at the Patient-Centered Outcomes, OPEN Health
London, United Kingdom

David Gebben

Health Economist, FDA - CDRH
Silver Spring, MD, United States

Yuanyuan Gu

Associate Professor, Macquarie University Centre for the Health Economy
Sydney, Australia

Stephane Hess

Leeds, United Kingdom

Ellen Janssen, BA

Director, Benefit-Risk, Janssen Research & Development, LLC
Baltimore, MD, United States

Deborah Marshall, PhD, BSc

Professor, Scientific Director Value and Impact, Alberta Children's Hospital Research Institute, University of Calgary
Calgary, AB, Canada

Bettina Ryll, PhD, MD

Founder, Melanoma Patient Network Europe
Uppsala, Sweden

Mo Zhou, PhD

Director, Patient Experience Data Science, Novartis
East Hanover, NJ, United States
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×